Home > Patient Guide > Clinical Trials

Clinical Trials

Here at the Pancreas Center, advancing the early detection, care, and treatment of pancreatic cancer through research is part of our mission. Already intrepid in our current treatment tactics, we believe there are still opportunities for novel and improved detection and therapeutic options yet to be developed. The Pancreas Center team is committed to being on the leading edge of developing these breakthrough therapies by better understanding the causes of pancreatic cancer through basic research and exploring innovative treatments through translational research and clinical trials.

Below is a listing of Pancreas Center clinical trials that are currently open for enrollment. If you have any questions about the trials listed, please contact the enrolling physician, or contact the Pancreas Center clinical trials coordinator at 212.305.9467. It is important to understand that participation in any clinical trial is completely voluntary for the patient. Common reasons for joining a clinical trial include:
  • Playing a more active role in your own health care
  • Gaining access to innovative screening and therapies before they become widely available
  • Helping others by contributing to advancements in medical research
List of Trials (Click titles for more information)

Trial: Phase II Study of Gemzar, Taxotere and Xeloda (GTX) for Adjuvant Pancreatic Cancer Treatment
Description: GTX is a combination of Gemcitabine, Taxotere and Xeloda, which has been shown to be synergistic in laboratory models. The primary aim of this study is to determine whether there is any toxicity associated with the new regimen.

Trial: Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High Risk Individuals
Description: The specific aims of this project are to create a registry, as well as a blood and a tissue bank for individuals with and at high-risk for pancreatic cancer. The personal data derived from the registry, correlated with biological information derived from the tissue specimens will allow for future investigative studies of pancreatic cancer etiology and tumor biology.

Trial: Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
Description: The primary goal is to determine the radiologic response rate to this regimen in progressive, metastatic, differentiated neuroendocrine cancers, including carcinoid tumors and excluding small cell cancer of lung or other origin (e.g. GI tract) which are poorly differentiated.

Trial: Depression and Tumor Burden in Pancreatic Adenocarcinoma Study
Description: The purpose of the study is to assess the relationship between mood and tumor size in pancreatic cancer

Trial: Molecular Genetics and Epidemiology Study
Description: To determine the frequency of gene mutations in patients with, or at a high risk for developing, pancreatic cancer

If you are interested in other clinical trial opportunities within Columbia University, click here.


What to expect from an appointment with a specialist:

Appointment Request Form
Directions to the Center